Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic rhinosinusitis with nasal polyps and COPD it is being developed for.

Episode metadata supplied by the publisher feed · Published Feb 11, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

0:00 13:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 13 minutes long.

When was this BiotechTV - News episode published?

This episode was published on February 11, 2026.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!